RS-601 is a potent dual leukotriene D4/thromboxane A2 inhibitor with bronchodilatory effects; it significantly inhibits U-46619- and LTD4-induced bronchoconstriction in a dose-dependent manner in guinea pigs; it also markedly suppresses the late-phase response and LPS-induced airway hyperresponsiveness (AHR) at a dose of 10 mg/kg, and effectively inhibits AHR at doses of 3 and 10 mg/kg.